Literature DB >> 6160858

Impaired antigen-specific suppressor cell activity in patients with rheumatoid arthritis.

E C Keystone, D D Gladman, R Buchanan, D Cane, L Poplonski.   

Abstract

Antigen-specific suppressor cell activity of peripheral blood mononuclear cells was investigated in 20 patients with rheumatoid arthritis (RA) and 16 age- and sex-matched healthy controls. Suppressor cell activity was generated by priming peripheral blood mononuclear cells with high dose antigen (ovalbumin) and adding the washed primed or control (unprimed) cells to autologous, optimally stimulated, target plaque forming cell (PFC) cultures. The ability of the primed cells to interfere with an optimal ovalbumin specific PFC response in the target culture was used as a measure of antigen-specific suppressor cell activity. The results demonstrated that the mean (+/- SE) PFC response of the rheumatoid patients (669 +/- 76 PFC/10(6) cells) was not statistically different from that of the normal controls (722 +/- 83 PFC/10(6) cells), P = 0.1. However, reduced suppressor cell activity was observed in the rheumatoid patients relative to controls (46.4 +/- 4.2% versus 64.6 +/- 2.7% suppression, respectively; P < 0.001). No correlation was demonstrated between suppressor cell activity in rheumatoid patients and disease activity or therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160858     DOI: 10.1002/art.1780231103

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Effects of methyl-B12 on the in vitro immune functions of human T lymphocytes.

Authors:  T Sakane; S Takada; H Kotani; T Tsunematsu
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

2.  Aberrations in lymphocyte subpopulations and function during psychological stress.

Authors:  B Dorian; P Garfinkel; G Brown; A Shore; D Gladman; E Keystone
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

3.  Aberrant T-regulation in rheumatoid arthritis and IgA nephropathy affects CD5+ and CD5- B lymphocytes equally.

Authors:  B M Jones; I K Cheng; R W Wong
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

4.  Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition.

Authors:  M Goto; M Fujisawa; A Yamada; T Okabe; F Takaku; M Sasano; K Nishioka
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

5.  Autoantibodies against Tmu and B lymphocytes in patients with rheumatoid arthritis.

Authors:  C J Meijer; J Cnossen; G J Lafeber; M J Damsteeg; A Cats
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

6.  In vitro immunoglobulin synthesis by lymphocytes from patients with rheumatoid arthritis. I. Effect of monocyte depletion and demonstration of an increased proportion of lymphocytes forming rosettes with mouse erythrocytes.

Authors:  C Plater-Zyberk; M F Clarke; K Lam; P A Mumford; G R Room; R N Maini
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

7.  Evidence for B cell activation in patients with active rheumatoid arthritis.

Authors:  P Y Youinou; W L Irving; M Shipley; J Hayes; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

8.  Impaired release of a T-cell specific suppressor factor in rheumatoid arthritis.

Authors:  C Lau; S Budz-Tymkewycz; M Ramsden; P Lee; E C Keystone
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

9.  Spontaneous and aggregated IgG induced rheumatoid factor producing cells in rheumatoid arthritis.

Authors:  E J Pisko; R A Turner; M Panetti; S L Foster; E Heise
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

10.  Increment of CD8S6F1 cells in synovial fluid from patients with rheumatoid arthritis.

Authors:  Y Ueki; K Eguchi; S Miyake; S Nagataki; Y Tominaga
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.